Qiagen Balance Sheet Health
Financial Health criteria checks 6/6
Qiagen has a total shareholder equity of $3.5B and total debt of $2.0B, which brings its debt-to-equity ratio to 57%. Its total assets and total liabilities are $6.3B and $2.7B respectively. Qiagen's EBIT is $472.0M making its interest coverage ratio -17.5. It has cash and short-term investments of $1.5B.
Key information
57.0%
Debt to equity ratio
US$2.01b
Debt
| Interest coverage ratio | -17.5x |
| Cash | US$1.48b |
| Equity | US$3.53b |
| Total liabilities | US$2.74b |
| Total assets | US$6.27b |
Recent financial health updates
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Recent updates
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S
Oct 11An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued
Sep 24With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For
May 21Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
May 03Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
Feb 13Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings
Jan 23These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued
Oct 24Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
Sep 09Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jul 17Qiagen: Major Asset Growth Needed In Post-Covid World
Jun 22Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Apr 18Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued
Feb 14Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated
Feb 07If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity
Jan 18Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases
Jan 06A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jan 04Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati
Dec 13Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M
Nov 07We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Qiagen stock down after BHF downgrades rating to Neutral
Oct 10Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Oct 04Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate
Sep 14Financial Position Analysis
Short Term Liabilities: QGEN's short term assets ($2.5B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: QGEN's short term assets ($2.5B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: QGEN's net debt to equity ratio (15.1%) is considered satisfactory.
Reducing Debt: QGEN's debt to equity ratio has reduced from 71.4% to 57% over the past 5 years.
Debt Coverage: QGEN's debt is well covered by operating cash flow (31.5%).
Interest Coverage: QGEN earns more interest than it pays, so coverage of interest payments is not a concern.